Bryn Mawr Trust CO Nuvectis Pharma, Inc. Transaction History
Bryn Mawr Trust CO
- $5.88 Billion
- Q3 2025
A detailed history of Bryn Mawr Trust CO transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 61 shares of NVCT stock, worth $409. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61Holding current value
$409% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NVCT
# of Institutions
50Shares Held
3.23MCall Options Held
44.5KPut Options Held
50.1K-
Vanguard Group Inc Valley Forge, PA667KShares$4.47 Million0.0% of portfolio
-
Ronit Capital LLP563KShares$3.77 Million5.37% of portfolio
-
Iridian Asset Management LLC406KShares$2.72 Million1.02% of portfolio
-
Baldwin Brothers LLC350KShares$2.35 Million0.15% of portfolio
-
Geode Capital Management, LLC Boston, MA285KShares$1.91 Million0.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $98.3M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...